Avelumab in gastric cancer.

Roviello G; D'Angelo A; Generali D; Pittacolo M; Ganzinelli M; Iezzi G; Manzini N; Sobhani N

doi:10.2217/imt-2019-0011

Back

Journal article

Avelumab in gastric cancer.

Roviello G Department of Health Sciences, University of Florence, Viale Pieraccini, 6, 50139 Florence, Italy.
D'Angelo A Department of Biology & Biochemistry, University of Bath, Bath BA2 7AY, United Kingdom.
Generali D Breast Cancer Unit, ASST Cremona, Viale Concordia 1, 26100 Cremona, Italy.
Pittacolo M Department of Orthopedics & Orthopedic Oncology, University of Padova, Italy.
Ganzinelli M Thoracic Unit, Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Iezzi G Department of Biomedicine, University of Basel, Basel, Switzerland.
Manzini N General Surgery Unit, Department of Medical, Surgical and Health Sciences Cattinara University Hospital, Azienda Sanitaria Universitaria Integrata di Trieste, Trieste, Italy.
Sobhani N Breast Cancer Unit, ASST Cremona, Viale Concordia 1, 26100 Cremona, Italy.

2019-05-08

Published in:

Immunotherapy. - 2019

English Gastric cancer (GC) is the fifth most common malignancy and the third cause of cancer-related deaths worldwide. Currently, surgery and chemotherapy remain the main therapeutic options and the prognosis of the disease is still poor in the metastatic setting. Avelumab is a human IgG1 antibody directed against PD-L1 approved for Merkel cell carcinoma and urothelial carcinoma that could be useful also for the treatment of GC. This review describes the chemical structure, the pharmacologic properties and the current knowledge of the efficacy of avelumab in the treatment of GC from the data available on the first and later phase clinical trials. The ongoing studies testing this drug either alone or in combination with other drugs are also described.

Language